PTCY keeps on giving!

Vedran Radojcic; Leo Luznik

doi:10.1182/blood.2019002284

PTCY keeps on giving!

Vedran Radojcic, Leo Luznik

School of Medicine

Research output: Contribution to journal › Review article › peer-review

2 Scopus citations

Abstract

In this issue of Blood, Battipaglia and colleagues report improved outcomes for patients receiving posttransplant cyclophosphamide (PTCY) vs antithymocyte globulin (ATG) as backbone of their immunosuppression regimen after 1-antigen mismatched unrelated donor (MMUD) allogeneic hematopoietic cell transplantation (alloHCT) for treatment of acute myeloid leukemia (AML).¹

Original language	English (US)
Pages (from-to)	848-849
Number of pages	2
Journal	Blood
Volume	134
Issue number	11
DOIs	https://doi.org/10.1182/blood.2019002284
State	Published - Sep 12 2019

ASJC Scopus subject areas

Biochemistry
Immunology
Hematology
Cell Biology

Access to Document

10.1182/blood.2019002284

Cite this

@article{6a36c17a98f84f72ad3c42c81592af26,

title = "PTCY keeps on giving!",

abstract = "In this issue of Blood, Battipaglia and colleagues report improved outcomes for patients receiving posttransplant cyclophosphamide (PTCY) vs antithymocyte globulin (ATG) as backbone of their immunosuppression regimen after 1-antigen mismatched unrelated donor (MMUD) allogeneic hematopoietic cell transplantation (alloHCT) for treatment of acute myeloid leukemia (AML).1 ",

author = "Vedran Radojcic and Leo Luznik",

note = "Publisher Copyright: {\textcopyright} 2019 by The American Society of Hematology",

year = "2019",

month = sep,

day = "12",

doi = "10.1182/blood.2019002284",

language = "English (US)",

volume = "134",

pages = "848--849",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

number = "11",

}

TY - JOUR

T1 - PTCY keeps on giving!

AU - Radojcic, Vedran

AU - Luznik, Leo

PY - 2019/9/12

Y1 - 2019/9/12

N2 - In this issue of Blood, Battipaglia and colleagues report improved outcomes for patients receiving posttransplant cyclophosphamide (PTCY) vs antithymocyte globulin (ATG) as backbone of their immunosuppression regimen after 1-antigen mismatched unrelated donor (MMUD) allogeneic hematopoietic cell transplantation (alloHCT) for treatment of acute myeloid leukemia (AML).1

AB - In this issue of Blood, Battipaglia and colleagues report improved outcomes for patients receiving posttransplant cyclophosphamide (PTCY) vs antithymocyte globulin (ATG) as backbone of their immunosuppression regimen after 1-antigen mismatched unrelated donor (MMUD) allogeneic hematopoietic cell transplantation (alloHCT) for treatment of acute myeloid leukemia (AML).1

UR - http://www.scopus.com/inward/record.url?scp=85072142532&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072142532&partnerID=8YFLogxK

U2 - 10.1182/blood.2019002284

DO - 10.1182/blood.2019002284

M3 - Review article

C2 - 31515227

AN - SCOPUS:85072142532

SN - 0006-4971

VL - 134

SP - 848

EP - 849

JO - Blood

JF - Blood

IS - 11

ER -

PTCY keeps on giving!

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this